This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cole, P. D. Articles by Bertino, J. R. Search for Related Content PubMed PubMed Citation Articles by Cole, P. D. Articles by Bertino, J. R.

Effects of Overexpression of -Glutamyl Hydrolase on Methotrexate Metabolism and Resistance¹

Department of Pediatrics, The Cancer Institute of New Jersey/Robert Wood Johnson University Hospital, New Brunswick, New Jersey 08901 [P. D. C., B. A. K., A. K. S., E. M.], and Department of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [R. G., D. B., J. R. B.]

Intracellular metabolism of methotrexate (MTX) to MTX-polyglutamates (MTXPG) is one determinant of cytotoxicity. Steady-state accumulation of MTXPG seems to depend on the activity of two enzymes: folylpolyglutamate synthetase (FPGS), which adds glutamate residues, and -glutamyl hydrolase (GGH), which removes them. Overexpression of GGH would be expected to decrease intracellular MTXPG, thereby increasing efflux of MTX and decreasing cytotoxicity. Increased expression of GGH has been shown to be associated with resistance to MTX in human sarcoma cell lines and a rat hepatoma cell line. To clarify the specific role of GGH in determining MTX sensitivity, we investigated the phenotype produced by forced GGH overexpression in two cell types. Furthermore, because MTX and folic acid share metabolic pathways, we measured the effects of GGH overexpression on folic acid metabolism. The full-length cDNA for GGH, subcloned into a constitutive expression vector, was transfected into a human fibrosarcoma (HT-1080) and a human breast carcinoma (MCF-7) cell line. Compared with the clones containing an empty vector, the GGH-overexpressing cells express 15- to 30-fold more GGH mRNA, more GGH protein, and 15- to 90-fold more GGH enzyme activity. GGH overexpression altered MTX accumulation and metabolism to long-chain polyglutamates. In contrast to expectations, however, GGH overexpression did not confer resistance to short MTX exposures in either cell line. Changes in MTX metabolism were found to be balanced by alterations in accumulation and metabolism of folic acid. The ratio of MTX:folate accumulation may be a better predictor of MTX cytotoxicity than the accumulation of either alone. We conclude that, at least for these two cell lines, GGH overexpression alone is insufficient to produce clinical resistance to MTX.

This article has been cited by other articles:

				I. Ifergan, G. Jansen, and Y. G. Assaraf The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695. [Abstract] [Full Text] [PDF]

				R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920. [Abstract] [Full Text] [PDF]

				A. Llombart-Cussac, M. Martin, N. Harbeck, R. M. Anghel, A. E. Eniu, M. W. Verrill, P. Neven, J. De Greve, A. S. Melemed, R. Clark, et al. A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer Clin. Cancer Res., June 15, 2007; 13(12): 3652 - 3659. [Abstract] [Full Text] [PDF]

				S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]

				K-J Sohn, F Smirnakis, D N Moskovitz, P Novakovic, Z Yates, M Lucock, R Croxford, and Y-I Kim Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate Gut, December 1, 2004; 53(12): 1825 - 1831. [Abstract] [Full Text] [PDF]

				J. C. Panetta, A. Wall, C.-H. Pui, M. V. Relling, and W. E. Evans Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of {gamma}-Glutamyl Hydrolase Activity Clin. Cancer Res., July 1, 2002; 8(7): 2423 - 2429. [Abstract] [Full Text] [PDF]